This DNA repair gene went rogue and exposed a cancer weakness
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- EXO1 overexpression was detected in 20–30% of breast and ovarian cancers as well as melanoma, testicular, cervical, and hepatobiliary cancers, with the strongest association seen in aggressive basal-like breast cancer, per the Penn State team.
- Excess EXO1 protein acts like molecular scissors that cut the wrong DNA, enlarging single-stranded gaps and degrading reversed replication forks in partnership with the MRE11 protein, generating toxic double-strand breaks.
- Olaparib, a PARP inhibitor currently reserved for BRCA-mutant cancers, shrank EXO1-overexpressing tumors in lab experiments as effectively as it shrinks BRCA-mutant tumors, according to the Nature Communications study.
- Cisplatin also worked against EXO1-overexpressing tumors, and lead author Alexandra Nusawardhana said lower doses could potentially achieve comparable tumor shrinkage with fewer side effects.
- Senior author George-Lucian Moldovan, a professor of molecular and precision medicine at Penn State College of Medicine, said EXO1 could serve as a biomarker to guide patients toward more personalized chemotherapy choices.
- Unlike BRCA mutations, EXO1 overexpression is not inherited, and the researchers do not yet know whether it directly causes cancer; they plan to pursue clinical trials in EXO1-overexpressing patients.
Why it matters: Olaparib and similar BRCA-targeted drugs are currently restricted to the minority of cancer patients who carry BRCA mutations. If EXO1 overexpression reliably flags a broader responder pool — 20–30% of breast and ovarian cancers alone, plus melanoma, cervical, testicular, and hepatobiliary tumors — thousands more patients without inherited BRCA mutations could become eligible for repair-targeted therapies, and lower cisplatin doses might spare them side effects.
